Sumanta Kumar Pal, MD, FASCO - Breaking New Ground in RCC Management: Expert Guidance on Leveraging Therapeutic Strategies

Go online to PeerView.com/FFQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the number of approved treatment strategies in renal cell carcinoma (RCC) grows, there are new opportunities to provide personalized medicine to patients in a variety of settings. Multi-targeted TKIs, immune checkpoint inhibitors, and combination strategies (dual checkpoint blockade and immune checkpoint inhibitor/TKI combinations) are now options in the frontline treatment of advanced disease, while recent data also show that immunotherapy-based combinations may improve survival in patient subpopulations with poor prognostic features. In this activity, based on a recent live symposium, a panel of experts reviews the latest efficacy and safety evidence for approved and emerging strategies for the treatment of patients with advanced RCC in the frontline and refractory settings and engages in discussions of relevant patient cases that will provide insight on bringing these therapeutic advances into the clinic. Featured topics include treatment selection and sequencing and addressing potential therapy-related toxicities. Upon completion of this activity, participants should be better able to: Assess treatment efficacy and safety of established and emerging therapies for patients with RCC; Design personalized treatments incorporating approved and emerging therapies utilizing current evidence and patient-, disease-, and treatment-specific factors for patients with RCC; and Develop best practices and evidence-based strategies to anticipate, mitigate, and manage various adverse events associated with modern treatments for patients with RCC.